Pain at 6 months or more; all doses Assessed by change from baseline, using a 0‐ to 100‐mm VAS, where higher scores indicate more pain) · people with diabetic peripheral neuropathy
1 finding from 1 review
Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptom quality and severity Assessed by NSS score (range of possible scores 0 to 9; higher scores indicate more symptoms) · the treatment of diabetic peripheral neuropathy
1 finding from 1 review
Adverse events · the treatment of diabetic peripheral neuropathy
Acetyl‐L‐carnitine showed no clear difference in adverse events compared with methylcobalamin (low certainty).
1 finding from 1 review
Functional impairment and disability Assessed by NIS or NDS at 6 months or more · people with diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy
1 finding from 1 review
Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptom quality and severity Assessed by change in symptom score on a validated screening questionnaire (NSS or MNSI) at 6 months or more · people with diabetic peripheral neuropathy
1 finding from 1 review
no estimate extracted
2 participants
GRADE not reported
Adverse events: any adverse event, adverse events requiring withdrawal, and serious adverse events · people with diabetic peripheral neuropathy
1 finding from 1 review
Pain at 6 months or more · the treatment of diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional impairment and disability Assessed by change in NDS score (range of possible scores from 0 (normal function) to 10 (maximal disability) · the treatment of diabetic peripheral neuropathy
1 finding from 1 review
Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
General health‐related quality of life · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Serious adverse events · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Fatigue Mental fatigue in moderate‐grade hepatic encephalopathy Wessely and Powell test Scale from 0 to 10 · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Non‐serious adverse events · patients with covert or overt hepatic encephalopathy
It is very uncertain whether acetyl‐L‐carnitine changes non‐serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of days in hospital (duration of hospitalisation) · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Blood ammonium levels · patients with covert or overt hepatic encephalopathy
1 finding from 1 review
Change in disability score · non‐ambulatory children with SMA types II and III
1 finding from 1 review